337 related articles for article (PubMed ID: 30908671)
1. Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.
Zhou Y; Kreek MJ
Alcohol Clin Exp Res; 2019 Jun; 43(6):1077-1090. PubMed ID: 30908671
[TBL] [Abstract][Full Text] [Related]
2. Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.
Zhou Y; Kreek MJ
Brain Res; 2019 Dec; 1724():146410. PubMed ID: 31469985
[TBL] [Abstract][Full Text] [Related]
3. V1b Receptor Antagonist SSR149415 and Naltrexone Synergistically Decrease Excessive Alcohol Drinking in Male and Female Mice.
Zhou Y; Rubinstein M; Low MJ; Kreek MJ
Alcohol Clin Exp Res; 2018 Jan; 42(1):195-205. PubMed ID: 29105118
[TBL] [Abstract][Full Text] [Related]
4. Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone.
Zhou Y; Crowley RS; Ben K; Prisinzano TE; Kreek MJ
Brain Res; 2017 May; 1662():75-86. PubMed ID: 28263712
[TBL] [Abstract][Full Text] [Related]
5. Involvement of GRK2 in modulating nalfurafine-induced reduction of excessive alcohol drinking in mice.
Zhou Y; Liang Y
Neurosci Lett; 2021 Aug; 760():136092. PubMed ID: 34197905
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice.
Zhou Y; Leri F; Low MJ; Kreek MJ
Pharmacol Biochem Behav; 2019 Jun; 181():28-36. PubMed ID: 30991059
[TBL] [Abstract][Full Text] [Related]
7. Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice.
Zhou Y; Crowley R; Prisinzano T; Kreek MJ
Neurosci Lett; 2018 Apr; 673():19-23. PubMed ID: 29496608
[TBL] [Abstract][Full Text] [Related]
8. Hypothalamic-specific proopiomelanocortin deficiency reduces alcohol drinking in male and female mice.
Zhou Y; Rubinstein M; Low MJ; Kreek MJ
Genes Brain Behav; 2017 Apr; 16(4):449-461. PubMed ID: 27870313
[TBL] [Abstract][Full Text] [Related]
9. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
10. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.
Inan S; Dun NJ; Cowan A
Neuroscience; 2009 Sep; 163(1):23-33. PubMed ID: 19524022
[TBL] [Abstract][Full Text] [Related]
11. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice.
Dunn A; Windisch K; Ben-Ezra A; Pikus P; Morochnik M; Erazo J; Reed B; Kreek MJ
Psychopharmacology (Berl); 2020 Aug; 237(8):2405-2418. PubMed ID: 32435819
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.
Kaski SW; White AN; Gross JD; Trexler KR; Wix K; Harland AA; Prisinzano TE; Aubé J; Kinsey SG; Kenakin T; Siderovski DP; Setola V
J Pharmacol Exp Ther; 2019 Nov; 371(2):487-499. PubMed ID: 31492823
[TBL] [Abstract][Full Text] [Related]
14. Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL/6J mice.
Zhang Y; Kreek MJ
Neuropharmacology; 2020 Oct; 176():108244. PubMed ID: 32702404
[TBL] [Abstract][Full Text] [Related]
15. mTORC1 pathway is involved in the kappa opioid receptor activation-induced increase in excessive alcohol drinking in mice.
Zhou Y; Liang Y; Kreek MJ
Pharmacol Biochem Behav; 2020 Aug; 195():172954. PubMed ID: 32470351
[TBL] [Abstract][Full Text] [Related]
16. Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.
Zamarripa CA; Naylor JE; Huskinson SL; Townsend EA; Prisinzano TE; Freeman KB
Psychopharmacology (Berl); 2020 May; 237(5):1471-1480. PubMed ID: 32006048
[TBL] [Abstract][Full Text] [Related]
17. Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion.
Liu JJ; Chiu YT; DiMattio KM; Chen C; Huang P; Gentile TA; Muschamp JW; Cowan A; Mann M; Liu-Chen LY
Neuropsychopharmacology; 2019 Apr; 44(5):939-949. PubMed ID: 30082888
[TBL] [Abstract][Full Text] [Related]
18. Essential structure of the κ opioid receptor agonist nalfurafine for binding to the κ receptor.
Nagase H; Fujii H
Curr Pharm Des; 2013; 19(42):7400-14. PubMed ID: 23448474
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
[TBL] [Abstract][Full Text] [Related]
20. Aticaprant (Clinically Developed Kappa-Opioid Receptor Antagonist) Combined With Naltrexone Prevents Alcohol "Relapse" Drinking.
Zhou Y; Zhou DC; Kreek MJ
J Pharm Pharmacol (Los Angel); 2022 May; 9(1):. PubMed ID: 35832748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
